As per the latest report by Renub Research titled “Global Allergic Conjunctivitis Market Report by Disease Type (Seasonal ALLERGIC Conjunctivitis (SAC), Perennial Allergic Conjunctivitis (PAC)), Drug class (Antihistamines & Mast Cell Stabilizers, Corticosteroids, Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies & Drug Stores, Others), Countries and Company Analysis, 2024-2032″ Global Allergic Conjunctivitis Market the Allergic Conjunctivitis Market is expected to reach US$ 2.40 Billion by 2032 from US$ 1.96 Billion in 2023, with a CAGR of 2.28% during 2024-2032. In recent times, allergic diseases have dramatically increased globally. Allergic conjunctivitis is a common ophthalmic disorder in which the eye’s conjunctiva develops an inflammation due to an allergic reaction resulting from an individual’s interaction with an allergen. The eyeball has a conjunctiva membrane, which is susceptible to irritation from allergens. Allergic conjunctivitis is the body’s reaction to potentially harmful substances. Drug treatments for allergic conjunctivitis include Zerviate, OTX-DP (Dexamethasone Insert), ADX-102, PRT2761, CVXL-0074, AK-002, Bertilimumab, Reproxalap, ST-266, SYL-116011.
Key Drivers of Global Allergic Conjunctivitis Treatment Market:
Growing occurrences of ocular allergies in metropolitan spaces due to increasing air pollution, in tandem with the increasing number of allergens in the atmosphere are anticipated to drive the growth of the allergic conjunctivitis industry throughout the forecast period. In addition, the advent of new therapies and drugs for treating ocular disorders is to aid the growth of the allergic conjunctivitis market.
COVID-19 Impact on Allergic conjunctivitis market:
The outbreak of the COVID-19 has not boded well for the allergic conjunctivitis market due to stringent lockdowns and apprehensions surrounding the coronavirus have shown to a dramatic drop in visits to ophthalmologists by patients. Further, with elective procedures suspended by most healthcare facilities globally, doctors and other professionals postponed treatments for mild to moderate ocular conditions. Against the backdrop of allergic conjunctivitis drugs developments, the market growth declined in 2020.
Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC) Hold Majority of Market in the Global Allergic Conjunctivitis Market:
On the basis of Disease Type, the Allergic Conjunctivitis market includes Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC), Vernal Keratoconjunctivitis (VKC), Atopic Keratoconjunctivitis (AKC), Giant Papillary Conjunctivitis (GPC). SAC (Seasonal allergic conjunctivitis) is the most common allergic conjunctivitis, representing over half of all cases. It is connected to specific pollens that release spores during May, June, August, and September. Itching is a dominant symptom in (SAC) seasonal allergic conjunctivitis diagnosis, burning watery/mucus discharge, and redness.
Besides, perennial allergic conjunctivitis is a year-round allergic disease. These allergic responses are often related to dust, animal dander, or other allergens present in the environment year-round. Symptoms are equivalent to seasonal allergic conjunctivitis but tend to be milder.
United States holds the significant market share:
Based on countries Allergic Conjunctivitis Market segmented into India, China, Japan, United States, United Kingdom, France, Spain, and Italy. The United States is the giant market for allergic conjunctivitis treatments. This is attributable to the widespread awareness of visual allergies in the country, the substantial prevalence of this disease, and significant players resulting in the takeoffs of advanced drugs. According to the Renub Research Statistics, around 58.3 Million people in the U.S. had allergic conjunctivitis in 2021.
Similarly, China’s allergic conjunctivitis treatment market is anticipated to proliferate due to the vast population base leading to increased demand for improved health care facilities. Rapid urbanization and raised particulate pollution have augmented the incidence of allergic conjunctivitis drugs in China.
Related Report:
Global Myocardial Infarction Market
Anti-Venom Market
Cancer Immunotherapy Market
Key Players:
Prominent players operating in the global allergic conjunctivitis market are Ocular Therapeutix Inc, Portola Pharmaceuticals Inc., Alcon, Santen Pharmaceutical Co., Ltd, and Novartis. These key players operating in the market are focusing on developing treatments for allergic conjunctivitis. For instance, in 2021, Alcon announced the broad retail availability of Pataday Once Daily Relief Extra Strength in the United States
Market Summary:
• Disease Type – Renub Research Report covers by Disease Type in the 4 viewpoints (Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC), Vernal Kerato Conjunctivitis (VKC), Atopic Kerato Conjunctivitis (AKC) And Giant Papillary Conjunctivitis (GPC))
• Drugs Profile – This Report covers by Drugs Profile in the 10 viewpoints (Zerviate, OTX-DP, ADX-102, PRT-2761, CVXL-0074, AK-002, Bertilimumab, Reproxalap, ST-266, SYL-116011)
• Country – We have covered by Allergic Conjunctivitis Market by 9 viewpoints by Country (India, China, Japan, United States, United Kingdom, France, Germany, Italy, and Spain)
• All the major players have been covered from 3 Viewpoints (Overview, Recent Development, and Revenue Analysis) Ocular Therapeutix Inc, Portola Pharmaceuticals Inc., Alcon, Santen Pharmaceutical Co., Ltd, and Novartis.
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Address: 225 Kristie Ln, Roswell, GA 30076
Email: info@renub.com
LinkedIn: https://linkedin.com/company/renub-research
Website: www.renub.com
